BUY Caplin Point Laboratories Limited — Kunal Saraogi
byKunal SaraogiHorizon: NA (inferred 1 year)11 Sept 2026via Zee Business (Live)
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·10 Sept · yesterday
Caplin Point's Unit Gets Colombia's INVIMA GMP Compliance Nod for Oncology Drugs
NewsGoogle News·5 Sept · 6d ago
Caplin Point Subsidiary Gets Colombian GMP Certification
NewsGoogle News·1 Sept · 1w ago
Caplin Steriles Gets 10 USFDA Observations at Gummidipoondi Facility
NewsGoogle News·22 Aug · 3w ago
Caplin Point Laboratories Limited announced its financial results for the quarter ended June 30, 2026. The company recommended a final dividend of Rs.4/- per equity share.
NSE · Outcome of Board Meeting·12 Aug · 4w ago
Caplin Point Labs schedules AGM with ₹8 per share dividend payout
NewsGoogle News·8 Sept · 2d ago
Caplin Point Laboratories: AGM Details and ₹8 Dividend
NewsGoogle News·3 Sept · 1w ago
Caplin Point Laboratories Ltd announced the outcome of its board meeting held on August 12, 2026. The board approved unaudited financial results, recommended a final dividend of Rs. 4/- per share, app
BSE · Board Meeting·12 Aug · 4w ago
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.